Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss
礼来(US:LLY) WSJ·2025-10-31 06:00行业市场动态 - 礼公司季度财报和诺和诺德公司主动收购要约确认720亿美元抗肥胖药物市场是医药行业最热门的领域之一 [1]